CHIA-CHI LINJANN-YUAN WANGYEONG-SHIAU PU2020-08-132020-08-1320130732-183Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84872471691&doi=10.1200%2fJCO.2012.43.7566&partnerID=40&md5=e6b094b135fd5d67fa5098333f801125https://scholars.lib.ntu.edu.tw/handle/123456789/512476[SDGs]SDG3axitinib; bevacizumab; ethambutol; interferon; isoniazid; pyrazinamide; rifampicin; sorafenib; temsirolimus; antineoplastic agent; axitinib; bevacizumab; drug derivative; imidazole derivative; indazole derivative; monoclonal antibody; rapamycin; temsirolimus; adult; article; bone metastasis; cancer chemotherapy; case report; computer assisted tomography; disease course; drug withdrawal; flank pain; human; kidney carcinoma; lung lavage; lung nodule; lung tuberculosis; male; Mycobacterium tuberculosis; nephrectomy; priority journal; thorax radiography; treatment duration; treatment response; kidney carcinoma; kidney tumor; microbiology; middle aged; phase 3 clinical trial (topic); randomized controlled trial (topic); tuberculosis; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Sirolimus; Tuberculosisjournal article10.1200/JCO.2012.43.7566231695072-s2.0-84872471691